Tejas Patil, MD and Jie Wu, PhD, Announced as Recipients of RETpositive/LUNGevity Research Award

LUNGevity Foundation and RETpositive awarded $340,000 across two 2026 research projects targeting drug resistance in RET-positive cancers: $140,000 to Tejas Patil at the University of Colorado Denver and $200,000 to Jie Wu at the University of Oklahoma. The studies will test approaches combining RET inhibitors with other drugs; these are research projects with potential to inform future treatments, not approved new therapies.

Analysis

This is a research signal, not a near-term earnings catalyst. The awards are small and preclinical/translational: neither project supplies human efficacy, safety, or enrollment data, so there is no basis to revise revenue expectations for RET inhibitors or ADCs. The investable implication is a watch item around combination strategies: if persister-cell targeting or ADC-plus-TKI approaches show durable activity, value could shift toward combination-ready drug portfolios and away from a thesis that resistance can be solved solely by successive RET inhibitors. That is a months-to-years possibility, not a days-to-weeks trade.

The optimistic framing that already-approved medicines may accelerate development should be discounted. Existing approval in another cancer does not establish a workable dose, tolerability, efficacy, or regulatory path in RET-positive disease; combinations can add toxicity and complicate treatment sequencing. A positive result could also benefit multiple drug developers, making attribution to any one company difficult. Conversely, failure would not invalidate the broader RET-targeted market, only these specific mechanisms.

There is no mapped public-company exposure in the supplied data and no named commercial drug partners, so avoid assigning this award to a ticker or treating it as a read-through for a specific issuer. The consensus risk is not that investors are underpricing a near-term breakthrough; it is that optimistic language may be mistaken for clinical validation. Reassess only on disclosed preclinical results followed by trial initiation, dose feasibility, and human response or durability data.

Key Decisions for Investors

• No position based on this announcement alone; the direct economic exposure is unverified and the research is too early to support a revenue or valuation change.
• Add a watch item for the two projects: seek data on the specific agents, combination dosing and toxicity, tumor-model durability, and whether resistance is delayed rather than merely reduced in short-term assays.
• For oncology holdings, monitor clinical updates over the next 1–3 years for RET-combination trials and evidence of durable benefit. Treat trial initiation as a development catalyst, not proof of commercial success.
• Falsify the combination thesis if follow-up work shows no durable activity across relevant models, an impractical toxicity/dose profile, or no progression from translational results to a clinical study.